LNTH Q3 2025 Earnings — Lantheus Holdings, Inc. Revenue & Financial Results | Market Cap Arena

LNTHLantheus Holdings, Inc.

$6B

Q3 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$384M+1.4% YoY

Gross Profit

$222M57.9% margin

Operating Income

$44M11.4% margin

Net Income

$28M7.2% margin

EPS (Diluted)

$0.41

QoQ Revenue Growth

+1.6%

Cash Flow

Operating Cash Flow

$105M

Free Cash Flow

$95M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$2.3B

Total Liabilities

$1.2B

Stockholders' Equity

$1.1B

Cash & Equivalents

$382M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$384M	$379M	+1.4%
Gross Profit	$222M	$242M	-8.2%
Operating Income	$44M	$134M	-67.4%
Net Income	$28M	$131M	-78.8%

Revenue Segments

Product

$377M34%

Radiopharmaceutical Oncology

$241M22%

PYLARIFY

$241M22%

Total Precision Diagnostics

$130M12%

DEFINITY

$82M7%

Techne Lite

$21M2%

Strategic Partnerships And Other

$14M1%

License and Royalty Revenues

$7M1%

Other Precision Diagnostics

$6M1%